243 related articles for article (PubMed ID: 29704658)
1. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ho JC; Hsieh ML; Chuang PH; Hsieh VC
Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Leung HW; Liu CF; Chan AL
Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
[TBL] [Abstract][Full Text] [Related]
7. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
Zhang P; Wen F; Li Q
Dig Liver Dis; 2016 Dec; 48(12):1492-1497. PubMed ID: 27486048
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
[TBL] [Abstract][Full Text] [Related]
10. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Rognoni C; Ciani O; Sommariva S; Tarricone R
Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib for the treatment of advanced hepatocellular carcinoma.
Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
[TBL] [Abstract][Full Text] [Related]
12. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
Parikh ND; Singal AG; Hutton DW
Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
Shlomai A; Leshno M; Goldstein DA
PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
Carr BI; Carroll S; Muszbek N; Gondek K
J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Cai H; Zhang L; Li N; Zheng B; Liu M
J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
[No Abstract] [Full Text] [Related]
[Next] [New Search]
